Project: REPRogramming tumors INTo immune cells: a revolutionary gene therapy to treat cancer.
| Acronym | REPRINT (Reference Number: 115376) |
| Duration | 01/10/2021 - 01/10/2024 |
| Project Topic | We will deliver TrojanDC: a novel gene therapy for hard-to-treat solid tumors with primary focus on Melanoma stage 3-4. TrojanDC is administered intra-tumorally and employs a unique mode-of-action in which cancer cells are reprogrammed into antigen-presenting dendritic cells that elicit a strong and specific anti-tumor response. In this project, we will demonstrate TrojanDC’s efficacy and safety, thereby enabling GMP-like production and regulatory filing for first-in-human studies. |
| Network | Eurostars 2 |
| Call | Eurostars Cut–off 15 |
Project partner
| Number | Name | Role | Country |
|---|---|---|---|
| 1 | Antineo | Partner | France |
| 2 | Asgard Therapeutics AB | Coordinator | Sweden |
| 3 | InSphero AG | Partner | Switzerland |
| 4 | Lund University - Cell Reprogamming in Hematopoiesis and Immunity Group | Partner | Sweden |